Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: J Magn Reson Imaging. 2015 Feb 20;42(4):936–945. doi: 10.1002/jmri.24871

Figure 2.

Figure 2

Ktrans change in 0.5-mm thick peripheral tumor region and tumor volume change in two human head and neck cancer mouse models. (a, b) Ktrans change in 0.5-mm thick peripheral region of (a) SCC1 and (b) OSC19 tumors for 3 and 7 days after therapy initiation. (c, d) Volume change of (c) SCC1 and (d) OSC19 tumors for 3 and 7 days after therapy initiation. Six groups of animals (n=4–5 per group) were untreated (served as control) or treated with anti-EMMPRIN antibody (EMMP), cisplatin, X-ray irradiation, anti-EMMPRIN antibody plus cisplatin (EMMP+Cis), and anti-EMMPRIN antibody plus X-ray irradiation (EMMP+X), respectively. Asterisk and hash mark represent statistical difference from control and anti-EMMPRIN treated groups, respectively.